Certain groups expressed “deep concern” over FDA allowing an OTC asthma inhaler to be sold again after it was removed from the market 7 years ago. Here’s why.
Despite concerns about a new opioid that is reportedly 1,000 times more powerful than morphine, FDA recently approved the new painkiller.
FDA approves the first new flu drug in 20 years. Here’s what’s different about it.
A pharma maker is voluntarily recalling several lots of a major heart medication. Here’s why.
Pharmacy benefit managers, cardiologists, and others praised a pharma maker for significantly reducing the price of its high cholesterol drug.
A novel treatment for patients with moderate-to-severe asthma is now on the market.
A new indication for rivaroxaban (Xarelto) has been approved by FDA.
A new study linking attention-deficit hyperactivity disorder (ADHD) drugs and Parkinson’s disease could cause prescribers to re-think prescribing the medications.
In the past week, the migraine prevention drug market has suddenly heated up, with 2 new approvals by FDA.
Here are the top 3 new approvals from FDA.